Disease | Number | Females1
| Age (y)2
| AQP4-IgG1,3
| MOG-IgG1,3
|
---|
NMO | 45 | 41 (91%) * | 50 (2-80) | 43 (96%) § | 3 (7%) |
 |  |  |  | 1,280 | 2,560 |
 |  |  |  | (40-40,960) | (160-2,560) |
HR-NMO | 53 | 34 (64%) | 48 (13-74) | 32 (60%) § | 7 (13%) |
 |  |  |  | 1,280 | 2,560 |
 |  |  |  | (20-20,480) | (640-5,120) |
ADEM | 33 | 20 (61%) | 12 (2-52) § | 0 (0%) | 14 (42%) § |
 |  |  |  | - | 2,560 |
 |  |  |  |  | (160-20,480) |
CIS | 32 | 22 (69%) | 34 (5-57) + | 1 (3%) | 2 (6%) |
 |  |  |  | 640 | (640; 5,120) |
MS | 71 | 43 (61%) | 40 (14-66) | 0 (0%) | 2 (3%) |
 |  |  |  |  | (160; 160) |
CTRL | 101 | 79 (78%) | 43 (14-84) | 0 (0%) | 3 (3%) |
 |  |  |  |  | 320 |
 |  |  |  |  | (160-640) |
p-value | Â | 0.003 | < 0.001 | < 0.001 | < 0.001 |
- P-value: groups were compared using1 Chi-Square test with Fisher's exact post-hoc test and2 Kruskal-Wallis test with Dunn's post-hoc test (data are shown as median with range);3 median titer level (range) of MOG-IgG or AQP4-IgG seropositive samples; * statistically different from HR-NMO, ADEM and MS; + statistically significant from NMO, HR-NMO and ADEM; § statistically significant from all other groups (p-values were corrected for multiple comparisons). Abbreviations: y = years, NMO = Neuromyelitis optica, HR-NMO = High-risk NMO, ADEM = acute disseminated encephalomyelitis, CIS = clinically isolated syndrome, MS = multiple sclerosis, CTRL = controls.